Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Take-home naloxone

Thara Kumar and Hans Rosenberg
CMAJ September 18, 2017 189 (37) E1192; DOI: https://doi.org/10.1503/cmaj.170600
Thara Kumar
Department of Emergency Medicine, University of Ottawa/The Ottawa Hospital, Ottawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans Rosenberg
Department of Emergency Medicine, University of Ottawa/The Ottawa Hospital, Ottawa, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hrosenberg33@gmail.com
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Naloxone is available without prescription in Canada

In 2016, naloxone was removed from the federal Prescription Drug List, and the National Association of Pharmacy Regulatory Authorities reclassified the drug as Schedule II, meaning pharmacists can dispense it without prescription.1,2 It is available in commercial formulations, including intranasal preparations, as well as in locally prepared take-home naloxone kits, available from some pharmacies, clinics, emergency departments and community health centres.

Most take-home naloxone kits contain similar equipment

Most take-home naloxone kits will contain two ampules of naloxone (0.4 mg per vial), two safety-engineered syringes, two ampule-opening devices, alcohol swabs, nonlatex gloves and a rescue breathing barrier. The average cost for a take-home naloxone kit is $35. However, many sites offer them free of charge.1

Multiple doses of naloxone may be required for overdoses related to high-potency opioids

In overdoses related to fentanyl, carfentanil and other synthetic opioids, multiple doses may be required to restore respiration. Most take-home naloxone kits include two doses, and additional doses can safely be administered every two to five minutes if there is no response.3 Naloxone should be used in conjunction with basic life support principles, such as rescue breathing, cardiopulmonary resuscitation and calling 911.

Take-home naloxone kits may reduce overdose-related mortality

Although there are limited data on this relatively new intervention, a systematic review published in 2016 looked at 22 observational studies in North America, Europe and Australia, and found that take-home naloxone programs led to improved survival rates among program participants.4

Take-home naloxone kits are not only for patients with current opioid abuse

Other at-risk populations include individuals who are on methadone or on high doses of prescription opioids, or who frequently use recreational drugs. Health practitioners can suggest take-home naloxone to family members and friends of at-risk individuals.5 Education and counselling regarding opioid use and abuse is an essential part of the distribution of take-home naloxone.

Footnotes

  • CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/170600-five

  • Competing interests: None declared.

  • This article has been peer reviewed.

  • Contributors: Both authors contributed to the conception of the work and reviewed all drafts and revisions. Both authors give final approval of the version to be published and agree to be accountable for all aspects of the work.

References

  1. ↵
    CCENDU Bulletin: The availability of take-home naloxone in Canada. Ottawa: Canadian Centre on Substance Abuse; 2016. Available: www.ccsa.ca/Resource%20Library/CCSA-CCENDU-Take-Home-Naloxone-Canada-2016-en.pdf (accessed 2017 July 20).
  2. ↵
    National drug schedules: Final recommendation on naloxone hydrochloride. Ottawa: National Association of Pharmacy Regulatory Authorities; 2016. Available: http://napra.ca/pages/home/default.aspx?id=3758 (accessed 2017 Apr. 4).
  3. ↵
    Naloxone for treatment of opioid overdose. Silver Spring (MD): US Food and Drug Administration; 2016 Oct. 5. Available: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM522690.pdf (accessed 2017 July 20).
  4. ↵
    1. McDonald R,
    2. Strang J
    . Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction 2016;111:1177–87.
    OpenUrl
  5. ↵
    Briefing note: Cost coverage of naloxone and take-home naloxone kits. Ottawa: Canadian Centre on Substance Abuse; 2016. Available: www.ccsa.ca/Resource%20Library/CCSA-Cost-Coverage-Naloxone-Tool-2016-en.pdf (accessed 2017 Mar. 3).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (37)
CMAJ
Vol. 189, Issue 37
18 Sep 2017
  • Table of Contents
  • Index by author

Podcast

Subscribe to podcast
Download MP3

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Take-home naloxone
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Take-home naloxone
Thara Kumar, Hans Rosenberg
CMAJ Sep 2017, 189 (37) E1192; DOI: 10.1503/cmaj.170600

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Take-home naloxone
Thara Kumar, Hans Rosenberg
CMAJ Sep 2017, 189 (37) E1192; DOI: 10.1503/cmaj.170600
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Naloxone is available without prescription in Canada
    • Most take-home naloxone kits contain similar equipment
    • Multiple doses of naloxone may be required for overdoses related to high-potency opioids
    • Take-home naloxone kits may reduce overdose-related mortality
    • Take-home naloxone kits are not only for patients with current opioid abuse
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Updating our language around substance use disorders
  • PubMed
  • Google Scholar

Cited By...

  • Updating our language around substance use disorders
  • Google Scholar

More in this TOC Section

  • A blistering variant of phlegmasia cerulea dolens from underlying squamous cell lung cancer
  • Parechovirus infections in infants
  • Radiation dermatitis in a patient treated for hepatocarcinoma
Show more Practice

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire